---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pathophysiology"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pathophysiology. Topics: EGFR overexpression, all HNSCC; Genomic alterations of HPV-negative tumors; Field cancerization in HPV-negative disease; EGFR, TGF-beta, and immune exclusion in HPV-negative disease; 3 further topics. 7 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/pathophysiology"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### EGFR overexpression, all HNSCC

> “EGFR is overexpressed in 80–90% of HNSCC tumours and is associated with poor overall survival (OS) and progression-free survival (PFS)”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.4-2"></a>

### Genomic alterations of HPV-negative tumors

> “HPV-negative tumours are enriched for CDKN2A and TP53 alterations, frequent focal deletions in other TSGs (such as NSD1, FAT1, NOTCH1 and SMAD4) and frequent focal amplification of the genes encoding the receptor tyrosine kinases EGFR, HER2 (also known as ERBB2) and FGFR1”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

> “Smoking-related HNSCCs demonstrate near universal loss-of-function TP53 mutations and CDKN2A inactivation with frequent copy number alterations including amplification of 3q26/28 and 11q13/22.”

Source: [Cancer Genome Atlas Network (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4311405/)

<a id="topic-2.2.1.4-3"></a>

### Field cancerization in HPV-negative disease

> “Rather, HPV-negative HNSCC arises from the grossly normal upper aerodigestive mucosa subject to ‘epithelial field cancerization’, where chronic exposure to carcinogens has resulted in molecular changes preconditioning towards malignant progression”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

<a id="topic-2.2.1.4-4"></a>

### EGFR, TGF-beta, and immune exclusion in HPV-negative disease

> “HPV-negative disease is often aggressive and is characterized by epidermal growth factor receptor (EGFR) overexpression, transforming growth factor-β (TGF-β) signaling, and poor tumor penetration of immune cells in the tumor microenvironment (TME), resulting in markedly worse survival.”
> “TGF-β–driven epithelial-mesenchymal transition and extracellular matrix dysregulation create a fibrotic TME that limits tumor penetration, promoting resistance to anti-EGFR and anti–PD-1 therapy.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-2.2.1.4-5"></a>

### Immune infiltration by HPV status

> “We found that HPV-positive tumors were much more strongly immune infiltrated compared with HPV-negative tumors”

Source: [Mandal et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5070962/)

<a id="topic-2.2.1.4-6"></a>

### TGF-beta in immune evasion and resistance to EGFR antibodies

> “Factors in the HNSCC TME, including IL-10 and TGFβ, also promote macrophage polarization to the immunosuppressive M2 phenotype”

Source: [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)

> “Specifically, it has been shown that elevated levels of TGF-β in the TME are associated with immune evasion and resistance to cetuximab therapy”
> “TGF-β can also induce EMT through its transactivation of EGFR, synergistically leading to increased tumor invasion and therapy resistance”

Source: [Britton et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11394608/)

<a id="topic-2.2.1.4-7"></a>

### TGF-beta-mediated resistance to cetuximab in preclinical models

> “Therefore, elevated levels of TGF-β in the tumor microenvironment enable tumor cells to evade ADCC and resist the antitumor activity of cetuximab”

Source: [Bedi et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3640459/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
